Approval for the clarion(r) multi-strategy cochlear implant hifocus electrode for pediatric use.  The device, as modified, will be marketed under the trade name clarion(r) multi-strategy cochlear implant (pediatric) hifocus electrode and is indicated for severely and profoundly hearing impaired children ages 18-months to 17-years.